The novel anti-androgen candidate galeterone targets deubiquitinating enzymes, USP12 and USP46, to control prostate cancer growth and survival

Metastatic castration resistant prostate cancer is one of the main causes of male cancer associated deaths worldwide. Development of resistance is inevitable in patients treated with anti-androgen therapies. This highlights a need for novel therapeutic strategies that would be aimed upstream of the...

Descripción completa

Detalles Bibliográficos
Autores principales: McClurg, Urszula L., Azizyan, Mahsa, Dransfield, Daniel T., Namdev, Nivedita, Chit, Nay C.T.H., Nakjang, Sirintra, Robson, Craig N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982776/
https://www.ncbi.nlm.nih.gov/pubmed/29861848
http://dx.doi.org/10.18632/oncotarget.25167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982776/
https://www.ncbi.nlm.nih.gov/pubmed/29861848
http://dx.doi.org/10.18632/oncotarget.25167

Ejemplares similares